PanGenomic Health Updates on Management Cease Trade Order

The latest announcement is out from PanGenomic Health, Inc. Class A ( (TSE:NARA) ).

PanGenomic Health Inc. has provided an update regarding a management cease trade order (MCTO) issued due to a delay in filing its audited annual consolidated financial statements for 2024. The delay was caused by the company’s inability to pay its auditors on time, but those payments have now been made. The company expects to complete the required filings by June 30, 2025, and the MCTO restricts the CEO and CFO from trading company securities until the filings are completed and the order is revoked. Shareholders are not affected by this order, and the company will continue to provide updates as required.

Spark’s Take on TSE:NARA Stock

According to Spark, TipRanks’ AI Analyst, TSE:NARA is a Underperform.

The overall stock score is driven by severe financial instability, with no revenue generation and increasing net losses. Technical analysis provides a mixed picture, suggesting potential short-term recovery but still reflecting overall negative momentum. The negative P/E ratio and lack of dividend yield further decrease the stock’s attractiveness.

To see Spark’s full report on TSE:NARA stock, click here.

More about PanGenomic Health, Inc. Class A

PanGenomic Health is a precision health company that has developed a self-care digital platform to deliver personalized, evidence-based information about natural treatments. The company’s initial focus is on supporting mental health, and it is registered as a British Columbia benefit company with a mission to promote and improve health and wellness by providing a technology platform that identifies plant-based solutions tailored to individual health profiles.

Average Trading Volume: 18,103

Technical Sentiment Signal: Buy

Current Market Cap: C$1.95M

For a thorough assessment of NARA stock, go to TipRanks’ Stock Analysis page.